Síndrome Sjogren
Estado: No Reclutando AúnA Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren’s Syndrome (POETYK SjS-1).
Para inscribirte contáctate a:
[email protected]
Principales Criterios de Inclusión:
- Satisfy the 2016 American College of Rheumatology/European League Against Rheumatism criteria for the classification of SjS with disease duration (from time of diagnosis) of at least 16 weeks prior to screening.
- Have moderate to severe SjS ESSDAI ≥ 5.
- Short duration of disease (≤ 10 years) before screening.
- A stimulated whole salivary flow (SWSF) ≥ 0.05 mililiters/minute (mL/minute).
- Positive anti-Sjögren’s syndrome-associated antigen A (anti-Ro/SSA) at screening.
- Laboratorio:Bristol Myers Squibb
- Área Terapéutica:Reumatología
- Fase del estudio:III
- Código de Estudio:IM011-1069
- Ver ensayo en Clinical Trials
Viña del Mar
- Hospital Dr. Gustavo Fricke
Santiago
- Hospital Sótero del Río
Santiago
- Surmedica
Santiago
- CTR Estudios SpA
Santiago
- Centro de Estudios Reumatológicos
Santiago
- Biomedica Research Group
Osorno
- Clínica Alemana de Osorno
Encuentra tu
ensayo clínico
Elige tu área de interés, patología o región, y accede a tu ensayo clínico.
Buscar ensayos >